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Abstract
Purpose Data on MitraClip procedural safety and effi-
cacy in the Netherlands are scarce. We aim to provide an
overview of the Dutch MitraClip experience.
Methods We pooled anonymised demographic and pro-
cedural data of 1151 consecutive MitraClip patients, from
13 Dutch hospitals. Data was collected by product spe-
cialists in collaboration with local operators. Effect on mi-
tral regurgitation was intra-procedurally assessed by trans-
oesophageal echocardiography. Technical success and de-
vice success were defined according to modified defini-
tions of the Mitral Valve Academic Research Consortium
(MVARC).
Results Median age was 76 (interquartile range 69–82)
years and 59% were males. Patients presented with ≥mod-
erate mitral regurgitation and a predominance of functional
mitral regurgitation (72%). Overall, 611 (53%) patients
were treated with one Clip, 486 (42%) with ≥2 Clips and
54 (5%) received no Clip. The number of patients with
≥2 Clips increased from 22% in 2009 to 52% in 2016.
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Device success and technical success were 91 and 95%,
respectively, and were consistent over the years. Signif-
icant reduction of mitral regurgitation by MitraClip was
achieved in 94% of patients and was observed more often
in patients with functional mitral regurgitation (95% vs.
91%, p = 0.025). Device time declined from 145 min in
2009 to 55 min in 2016.
Conclusion MitraClip experience in the Netherlands is
growing with excellent technical success and device suc-
cess. Over the years, device time decreased and more pa-
tients were treated with ≥2 Clips.
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Introduction
Mitral regurgitation (MR) has a 2% prevalence in the gen-
eral population and is more frequent in the elderly [1, 2].
Surgical treatment is considered the ‘gold standard’ for
patients with symptomatic severe mitral regurgitation [3].
However, a significant proportion (49%) of eligible patients
are denied for surgery because of age, comorbidities or poor
left ventricular function [4].
The MitraClip (Abbott Vascular, Menlo Park, CA) of-
fers a completely percutaneous mitral valve edge-to-edge
repair. The efficacy and safety of the MitraClip device have
been demonstrated in the EVEREST I (Endovascular Valve
Edge-to-Edge Repair Study) trial [5]. Subsequently, the
EVEREST II randomised controlled trial compared con-
ventional surgery with MitraClip in operable patients with
moderate-to-severe or severe, predominantly degenerative
MR [6]. MitraClip was associated with superior safety and
similar improvements in clinical outcomes. However, it was
less effective in reducing MR [6]. Based on these results,
the Food and Drug Administration approved MitraClip for
high-risk patients with symptomatic degenerative MR. In
European practice, the majority of patients treated with Mi-
traClip have functional MR [7, 8]. In this clinical setting,
MitraClip may improve survival and hospital readmissions
[9].
Data on the Dutch MitraClip experience are scarce. We
therefore aim to provide an informative overview of the cur-
rent MitraClip procedural safety and efficacy in the Nether-
lands.
Methods
This multicentre observational retrospective study collected
all patients (n = 1151) from 13 Dutch hospitals treated
with MitraClip between January 2009 and June 2016. All
patients were discussed in local multi-disciplinary heart
teams including interventional cardiologists, imaging spe-
cialist and cardiac surgeons, and were considered symp-
tomatic and at high operative risk. All patients provided
written informed consent for the MitraClip procedure.
Procedural data were prospectively and anonymously
collected by product specialists in collaboration with local
operators and, after approval of the participating centres,
retrospectively analysed. Effect on MR was intra-procedu-
rally (onsite) assessed by transoesophageal echocardiogra-
phy. The Medical Ethics Committee of the Erasmus Medi-
cal Center reviewed the study protocol and waived the need
for additional informed consent because of the non-inter-
ventional character of this retrospective study (MEC-2016-
423) using anonymous data collection. The investigation
conforms to the principles outlined in the Declaration of
Helsinki.
MitraClip procedure
The MitraClip device is a 4 mm wide, polyester-covered
cobalt chromium V-shaped clip with two movable arms and
grippers (Fig. 1a). All procedures are performed under gen-
eral anaesthesia, using fluoroscopic and transoesophageal
echocardiographic guidance. A 24-French guide catheter
is introduced in a femoral vein and delivered into the left
atrium after transseptal puncture (Fig. 1b). The clip de-
livery system is advanced through the guide catheter into
the left atrium and positioned above the origin of the re-
gurgitation jet, perpendicular to the mitral coaptation line
(Fig. 1c). The arms of the Clip are opened and advanced
into the left ventricle. The Clip is then gradually pulled
back towards the left atrium in order to grasp both mitral
valve leaflets (Fig. 1d). The grippers are lowered, the clip
is closed (Fig. 1e) and the leaflets are approximated result-
ing in a double mitral orifice (Fig. 1f). Before releasing the
Clip, the severity of MR is assessed and the transmitral gra-
dient is measured. If the result is satisfactory, the Clip can
be released. In case of inadequate MR reduction or a high
transmitral gradient, the Clip can be opened and reposi-
tioned or removed. More than 1 Clip may be necessary for
significant MR reduction.
Study endpoints and definitions
The primary endpoints were procedural safety expressed
in ‘technical success’ and procedural efficacy expressed in
‘device success’, both were modified from the Mitral Valve
Research Consortium (MVARC) criteria [10].
● Technical success is defined as successful deployment of
the device with absence of procedural mortality and free-
dom from emergency surgery.
● Device success is defined as proper placement of the de-
vice without procedural mortality and with reduction in
post-procedural MR by ≥1 grade from baseline and to an
absolute level of moderate MR.
● Significant MR reduction: reduction in post-procedural
MR by ≥1 grade from baseline.
● Device time is defined as the time from guide catheter
insertion to guide catheter removal.
Statistical analysis
Categorical variables are presented as frequencies and per-
centages, and compared with the use of the Pearson Chi
Square Test or the Fisher’s exact test, as appropriate. Con-
tinuous variables are presented as means (± standard devi-
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Fig. 1 a MitraClip device with two movable arms and grippers; b Guide catheter advanced into the left atrium after transseptal puncture; c Posi-
tioning of the MitraClip above the regurgitation jet perpendicular to mitral coaptation line; d The MitraClip is pulled back in order to capture both
leaflets; e The grippers are lowered and the arms are closed approximating the leaflets; and f creating a double mitral orifice. Image courtesy of
Abbott
ation – SD), in case of normal distribution, or medians (in-
terquartile range – IQR), in case of skewed distribution, and
compared with the use of the Student’s t-test or the Mann-
Whitney U test. Normality of the distributions was assessed
using the Shapiro-Wilk test. We used a two-sided alpha
level of 0.05 to indicate significance. Statistical analyses
were performed using SPSS software version 21.0 (SPSS
Inc., Chicago, Illinois, USA).
Results
A total of 1151 patients underwent percutaneous mitral
valve edge to-edge repair with the MitraClip device. Rel-
ative contributions of the participating centres are sum-
marised in Fig. 2a. The overall cohort had a median age
of 76 (IQR 69–82) years and 59% were males. All patients
presented with ≥moderate MR at baseline, with a clear
dominance of functional MR (72%) (Table 1). Overall, 611
(53%) patients were treated with one Clip, 486 (42%) with
≥2 Clips and 54 (5%) received no Clip (Table 2). The num-
ber of patients treated with ≥2 Clips increased from 22%
in 2009 to 52% in 2016 (Fig. 2). Significant MR reduction
(≥1 grade) was achieved in 94% of patients.
The overall device and technical success were 91 and
95%, respectively, and were consistent over the years
(Fig. 2b). Intra-procedural death and need for emergency
surgery occurred in 3 (0.3%) and 6 (0.5%) patients, respec-
tively (Table 2). The median device time declined from
145 (IQR 108–177) minutes in 2009 to 55 (IQR 34–86)
minutes in 2016 (Fig. 2b).
Degenerative vs. functional MR
Patients with degenerative MR were older (median age 82
[IQR 76–85] vs. 74 [IQR 67–79] years, p < 0.001), had
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Table 1 Baseline characteristics of patients undergoing MitraClip im-
plantation
Total population
2009–2016
(n = 1151)
Male, n (%) 684 (59)
Age, median (IQR) 76 (69–82)
Etiology MR
Degenerative, n (%) 198 (17)
Functional, n (%) 832 (72)
Mixed, n (%) 118 (10)
Unknown, n (%) 3 (0.3)
Severity of MR at baseline
Moderate, n (%) 19 (2)
Moderate-to-severe, n (%) 388 (34)
Severe, n (%) 744 (65)
LVEF <30%, n (%) 500 (43)
IQR interquartile range, MR mitral regurgitation, LVEF left ventricular
ejection fraction
Table 2 Procedural characteristics of patients undergoing MitraClip
implantation
Total population
2009–2016
(n = 1151)
Clips
0 Clips, n (%) 54 (5)
1 Clip, n (%) 611 (53)
≥2 Clips, n (%) 486 (42)
Device Time (min)a, median (IQR) 66 (42–103)
MR reduction
0, n (%) 75 (7)
1, n (%) 108 (9)
2, n (%) 587 (51)
3, n (%) 381 (33)
≥1, n (%) 1076 (94)
Device successb, n (%) 1049 (91)
Technical successc, n (%) 1097 (95)
Intra-procedural death, n (%) 3 (0.3)
Emergency surgery, n (%) 6 (0.5)
IQR interquartile range, MR mitral regurgitation
aDevice time: defined as the time from delivery system insertion to clip
delivery system removal
bDevice success: defined as proper placement of the device without
procedural mortality and with reduction in
post-procedural MR by ≥1 grade from baseline and to an absolute level
of moderate MR
cTechnical success: defined as successful deployment of the device
with absence of procedural mortality
and freedom from emergency surgery
more often severe MR at baseline (73% vs. 61%, p < 0.001)
and were more often treated with ≥2 Clips (50% vs. 39%,
p = 0.001) when compared to patients with functional MR.
Patients in the latter group had more often significant MR
reduction (95% vs. 91%, p = 0.025) (Fig. 3) and a shorter
device time (62 [IQR 40–99] minutes vs. 75 [IQR 49–110]
minutes, p < 0.001).
One vs. ≥two MitraClips
Patients treated with ≥2 Clips were more often males (68%
vs. 53%, p < 0.001) with degenerative MR (33% vs. 23%,
p < 0.001) and severe MR at baseline (81% vs. 53%, p <
0.001). Significant MR reduction was similar in both groups
(98% vs. 98%, p = 0.59) (Fig. 4) while median device time
was higher in ≥2 Clips group (86 [IQR 58–120] vs. 51 [IQR
35–75] minutes, p < 0.001).
Discussion
To date, more than 1250 patients have undergone MitraClip
treatment in the Netherlands. We present the largest Dutch
multi-centre MitraClip study including 1151 patients. Key
findings are: 1) MitraClip was predominantly used to treat
functional MR; 2) MitraClip was successful in reducing MR
in 94% of patients; 3) MitraClip was slightly more effective
in patients with functional MR; 4) Over the years, implan-
tation of ≥2 Clips became more frequent; 5) With growing
experience, procedure time decreased with preserved device
success and technical success.
Patient demographics in our study were comparable with
large European registries (i. e. ACCESS-Europe A Two-
Phase Observational Study of the MitraClip System in
Europe (ACCESS-EU) and German Transcatheter Mi-
tral Valve Interventions Registry [TRAMI]) but different
from the EVEREST-II trial. The EVEREST trial was con-
ducted in the USA and included younger patients (67.3 ±
12.8 years) with preserved left ventricular ejection fraction
(60 ± 10.1). In Europe, MitraClip is more often applied in
functional MR, which contrasts with the clear dominance
(73%) of degenerative MR in the USA (Table 3; [6–8]).
In our study, MitraClip seemed slightly more effective
in functional MR than in degenerative MR (95% vs. 91%,
p = 0.025). Intra-procedural death and moderate MR after
Clip implantation were comparable with the ACCESS-EU
and TRAMI registry (0.3% vs. 0% vs. 0% and 92% vs. 91%
vs. 97%, respectively), confirming the safety and efficacy
of MitraClip (Table 3).
Over the years, practice changed with a higher frequency
of implanting ≥2 Clips. Patients treated with ≥2 Clips were
more often males with degenerative MR and severe MR at
baseline. Patients with degenerative MR may have thicker
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Fig. 3 Comparison of reduction of mitral regurgitation in patients
with degenerative mitral regurgitation versus functional mitral regurgi-
tation. MR mitral regurgitation, DMR degenerative mitral regurgitation,
FMR functional mitral regurgitation
and more mobile leaflets and had (in our cohort) more
often severe MR at baseline, which may explain why these
patients in particular are treated with ≥2 Clips. A previous
study identified anterior leaflet thickness (OR 1.7 per mm
[95% CI; 1.16–2.57], p = 0.007) and a greater regurgitation
volume at baseline (OR 1.21 per 10 ml [95% CI; 1.0–1.3],
p = 0.01) as echocardiographic predictors for the need for
more than 1 Clip [11]. Another study showed that the vena
contracta (jet width) predicted need for >1 Clip (OR 2.5
0
10
20
30
40
50
60
70
80
90
100
0 grade 1 grade 2 grades 3 grades ≥1 grades
(%)
MR reduction
Overall 1 MitraClip ≥2 MitraClips
Overall p = 0.018
p = 0.59
p = 0.29
p = 0.001
p = 0.012
p = 0.59
Fig. 4 Comparison of mitral regurgitation reduction in patients
treated with 1 versus ≥2 MitraClips. MR mitral regurgitation
[95% CI; 1.2–5.3], p = 0.013) with 83% sensitivity and
90% specificity for a cut-off value of ≥7.5 mm [12]. The
increased device time in degenerative MR may also be ex-
plained by thicker and more mobile leaflets since this may
aggravate the grasping process. Another reason is simply
because of implantation of more Clips.
According to the latest European guidelines on valvular
heart disease, MitraClip may be considered in patients with
symptomatic severe primary and secondary MR, despite
optimal medical therapy, including cardiac resynchroniza-
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Table 3 Baseline and procedural characteristics of patients undergoing MitraClip implantation in different cohorts
MitraClip Netherlands ACCESS-EU Phase I German TRAMI Registry EVEREST-II
(n = 1151) (n = 567) n = 1064 n = 184
Male, n (%) 684 (59) 362 (64) 658 (62) 115 (63)
Age (years) 76 (69–82) 73.7 ± 9.6 75 (70–81) 67.3 ± 12.8
Etiology MR
Degenerative, n (%) 198 (17) 117 (23) 246 (29) 135 (73)
Functional, n (%) 832 (72) 393 (77) 590 (71) 49 (27)
Mixed, n (%) 118 (10) – – –
Unknown, n (%) 3 (0.3) – – –
Severity of MR at baseline
Moderate, n (%) 19 (2) 13 (2) 42 (5) 8 (4)
Moderate-to-severe, n (%) 388 (34) 230 (41) – 130 (71)
Severe, n (%) 744 (65) 324 (57) 827 (95) 46 (25)
LVEF <30%, n (%) 500 (43) 193 (34) 294 (33) N. A.
LVEF, mean ± SD N. A. N. A. N. A. 60 ± 10.1
Procedural
0 Clips, n (%) 54 (5) 2 (0.4) N. A. N. A.
1 Clip, n (%) 611 (53) (60) N. A. N. A.
≥2 Clips 486 (42) (40) N. A. N. A.
Severity of MR after Clip
moderate, n (%) 1057 (92) 475 (91) 417 (97) (77)
Moderate-to-severe, n (%) 57 (5) 39 (8) – 41 (23)
Severe, n (%) 37 (3) 7 (1) 17 (3) –
Device successa, n (%) 1049 (91) N. A. N. A. N. A.
Technical successb, n (%) 1097 (95) N. A. N. A. N. A.
Intra-procedural death, n (%) 3 (0.3) 0 (0) 0 (0) N. A.
Emergency surgery, n (%) 6 (0.5) N. A. N. A. N. A.
MR mitral regurgitation, LVEF left ventricular ejection fraction, SD standard deviation
aDevice success: defined as proper placement of the device without procedural mortality and with reduction in post-procedural MR by ≥1 grade
from baseline and to an absolute level of moderate MR
bTechnical success: defined as successful deployment of the device with absence of procedural mortality and freedom from emergency surgery
tion therapy, who fulfil the echo criteria of eligibility, are
judged inoperable or at high surgical risk by a heart team,
and have a life expectancy greater than 1 year (recommen-
dation Class IIb, level of evidence C) [3]. The American
guidelines consider transcatheter mitral valve repair only
for severely symptomatic patients with chronic severe pri-
mary MR who have favourable anatomy for the repair pro-
cedure and a reasonable life expectancy, but who have a pro-
hibitive surgical risk because of severe comorbidities and
remain severely symptomatic despite optimal guideline-di-
rected medical therapy for heart failure (recommendation
Class IIb, level of evidence B) [13]. Yet, a wealth of recent
clinical data underscores procedural safety and efficacy of
MitraClip and a favourable longer-term outcome in selected
patients. MitraClip seems an excellent treatment strategy in
patients who are deemed at very high or prohibitive op-
erative risk by heart team consensus. Several studies have
shown significant MR reduction in the vast majority of high-
risk patients, resulting in positive left ventricular remod-
elling and improvement of functional capacity [14, 15].
Also, heart failure patients who do not respond effec-
tively to cardiac resynchronisation therapy and have at least
moderate MR can improve with MitraClip. Auricchio et al.
showed that 73% of cardiac resynchronization therapy non-
responders (with functional MR) improved in functional
class, and had increased left ventricular ejection fraction
and reduced ventricular volumes after MitraClip treatment
[16].
Ongoing randomised trials further elaborate on the value
of MitraClip in functional MR. The MATTERHORN (Mi-
tral vAlve reconsTrucTion for advancEd Insufficiency of
Functional or iscHaemic ORigiN) trial, is comparing Mi-
traClip with reconstructive mitral valve surgery in high-
risk patients with moderate-to-severe functional MR. The
Cardiovascular Outcomes Assessment of the MitraClip Per-
cutaneous Therapy for Heart Failure Patients with Func-
tional Mitral Regurgitation (COAPT) trial is investigating
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the safety and efficacy of MitraClip versus optimal medical
treatment (OMT) in patients with moderate-to-severe or se-
vere functional MR who have been assessed as not eligible
for mitral valve surgery.
The Multicentre Study of Percutaneous Mitral Valve Re-
pair MitraClip Device in Patients With Severe Secondary
Mitral Regurgitation (MITRA-FR) is comparing the safety,
efficacy and the cost-effectiveness of OMT versus OMT
plus MitraClip in patients with severe secondary mitral re-
gurgitation.
Expectedly, focused guidelines on valvular heart dis-
ease will be updated in the foreseeable future and include
stronger recommendations for MitraClip. For now, our
study demonstrated substantial MitraClip experience in the
Netherlands with excellent procedural safety and efficacy.
Limitations
Given the retrospective observational character of this study
and the onsite assessment of MR (i. e. absence of echo core
lab), potential self-reporting bias may be introduced. Spe-
cific echocardiographic (quantitative) parameters such as
regurgitation volume and jet width were not available. In
addition, data were limited to procedural outcome. Follow-
up data are needed to evaluate the durability of device suc-
cess.
Long-term efficacy may reveal recurrence of MR
(grade 3 or 4) as shown by the EVEREST-II trial and AC-
CESS-EU study with more than moderate MR recurrence
rates of 21% at 12 months in both studies. Furthermore,
we also acknowledge that complications such as stroke,
bleeding and vascular complications, although rare, may
occur during follow-up.
Conclusion
MitraClip experience in the Netherlands is growing with
excellent technical success and device success. Over the
years, the device time decreased and more patients were
treated with ≥2 Clips.
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